Cognivue

Cognivue®’s FDA-cleared technology digitally assesses cognitive functioning. With two devices, Cognivue Clarity® and the abbreviated screening of Cognivue Thrive®, we strive to deliver on our mission to provide cognitive assessment tools to a broad range of healthcare providers for the early detection of cognitive changes. Early detection allows individuals to address modifiable risk factors sooner, potentially reducing the risk of cognitive decline. Cognivue’s technology was designed to objectively, quantitatively and reliably identify changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It allows clinicians the opportunity to establish a baseline cognitive score that can be monitored over time. Immediate test results and scores available on completion of the assessment/screening, formatted to an easy-to-read report to inform clinical decision making.